A Phase 4 interventional study of Restylane-L® and Restylane-L® Lyft in Cosmetic Techniques, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A prospective, trial to quantitatively and qualitatively compare the dermal fillers for the treatment of age related aesthetic changes.
Dermal fillers have been approved for the treatment of age related aesthetic changes, including facial volume loss, and attenuation of the static and dynamic rhytid. Despite widespread use of volumizing fillers there is little data quantifying the subjective benefit of these minimally invasive treatments from the patient perspective. Furthermore, there is little data comparing the subjective benefit with true objective volumetric results. Such data will provide much needed information for patient counselling and treatment optimization for patient perceived outcomes.
This study is to determine the patient reported outcomes of three different dermal fillers and establish the volumetric changes over 90 days. Screening will be performed during the patient's office visit. Approximately 100 patients will be enrolled. Patients will participate up to 90 days (Day 1, 14 days, 28 days, and 90 days).
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 233 are open to participants now.
Of its 159 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hyaluronic acid
Drug: Restylane-L® · Drug: Restylane-L® Lyft · Drug: Restylane Silk®
Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
Also known as: Hyaluronic acid gel
Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
Also known as: Hyaluronic acid gel
Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Also known as: Hyaluronic acid gel
Patient Satisfaction With Validated FACE-Q Aesthetics Survey
Absolute Change of the Patient Satisfaction using the validated FACE-Q Aesthetics questionnaire for patient reported assessment of treatment by domain. The absolute change from the patient reported outcome score prior to injection to the patient reported score immediate post-injection. Increase in numeric value indicates the larger patient reported improvement, except for psychosocial distress module where a decrease in numeric value indicates patient improvement. Maximum change 99 and Minimum Change 0.
Time frame: 2 week post injections
Correlate Patient Satisfaction With Volumetric Measurements
Linear correlation of relative volumetric change over relative patient satisfaction scale change. These values are reported as correlation coefficients and are unit less.
Time frame: upto 90 days
Volumetric Changes of Treatment
3-dimensional photography to measure volumetric changes in each treatment
Time frame: immediately post injection, 2 weeks, 4 weeks, and 12 weeks
| Milestone | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Started | 101 |
| Completed | 101 |
| Not completed | 0 |
Absolute Change of the Patient Satisfaction using the validated FACE-Q Aesthetics questionnaire for patient reported assessment of treatment by domain. The absolute change from the patient reported outcome score prior to injection to the patient reported score immediate post-injection. Increase in numeric value indicates the larger patient reported improvement, except for psychosocial distress module where a decrease in numeric value indicates patient improvement. Maximum change 99 and Minimum Change 0.
| score on a scale | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Satisfaction with Facial Appearance. (Maximum change 99 and Minimum Change 0). | 28.0 (17.0 to 41.0) |
| Aging Appraisal. (Maximum change 99 and Minimum Change 0). | 24.0 (8.5 to 41.5) |
| Appraisal of Lines: Nasolabial Folds. (Maximum change 99 and Minimum Change 0). | 36.0 (12.0 to 58.0) |
| Appraisal of Lines: Marionette Lines. (Maximum change 99 and Minimum Change 0). | 36.0 (19.0 to 58.0) |
| Satisfaction with Lips. (Maximum change 99 and Minimum Change 0). | 23.5 (4.5 to 41.0) |
| Satisfaction with Cheekbones. (Maximum change 99 and Minimum Change 0). | 32.0 (17.0 to 53.5) |
| Satisfaction with Cheeks. (Maximum change 99 and Minimum Change 0). | 43.0 (23.0 to 60.0) |
| Satisfaction with Lower Face and Jawline. (Maximum change 99 and Minimum Change 0). | 35.0 (20.0 to 55.0) |
| Psychological Function. (Maximum change 99 and Minimum Change 0). | 13.0 (0.0 to 31.0) |
| Social Function. (Maximum change 99 and Minimum Change 0). | 8.0 (0.0 to 29.0) |
| Appearance-Related Psychosocial Distress. (Maximum change 99 and Minimum Change 0). | -12.0 (-29.0 to 0.0) |
Linear correlation of relative volumetric change over relative patient satisfaction scale change. These values are reported as correlation coefficients and are unit less.
| correlation coefficient (unit less) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| 2 weeks post injection | 0.0226 (-0.2779 to 0.3232) |
| 4 weeks post injection | -0.1796 (-0.4691 to 0.1099) |
| 12 weeks post injection | -0.3692 (-0.5934 to -0.1451) |
3-dimensional photography to measure volumetric changes in each treatment
| cc | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| post injection | 9.86 (7.37 to 12.6) |
| 2 weeks | 8.80 (6.30 to 11.0) |
| 4 weeks | 7.63 (5.85 to 10.6) |
| 12 weeks | 5.79 (3.20 to 9.38) |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Restylane-L®, Restylane-L® Lyft, and Restylane Silk® | 0/101 (0%) | 0/101 (0%) | 0/101 (0%) |
| Age, Continuous(years) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Median | 53.2 (49.1 to 56.9) |
| Sex: Female, Male(Participants) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Female | 101 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Race — African American/Black | 8 |
| Race — Caucasian/White | 92 |
| Race — Asian | 1 |
| BMI(kg/m^2) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Median | 24.4 (21.8 to 27.6) |
| Smoking History(Participants) | Restylane-L®, Restylane-L® Lyft, and Restylane Silk® |
|---|---|
| Never | 62 |
| Current | 11 |
| Former | 27 |
| Unknown | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Feb 2024, 42 months.
Results were first posted in Sep 2024, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid